<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-028X</journal-id>
<journal-title><![CDATA[Vaccimonitor]]></journal-title>
<abbrev-journal-title><![CDATA[Vaccimonitor]]></abbrev-journal-title>
<issn>1025-028X</issn>
<publisher>
<publisher-name><![CDATA[Finlay Ediciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-028X2002000300003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Validación de una técnica colorimétrica para la determinación de carbohidratos]]></article-title>
<article-title xml:lang="en"><![CDATA[Validation of a colorimetric technique for carbohydrate determination]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuello]]></surname>
<given-names><![CDATA[Maribel]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[Yusimí]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[Osmir]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Finlay  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2002</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2002</year>
</pub-date>
<volume>11</volume>
<numero>3</numero>
<fpage>11</fpage>
<lpage>14</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-028X2002000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-028X2002000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-028X2002000300003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[La adecuada estandarización de un ensayo analítico, seguido de la validación del método y la homogeneidad de los reactivos químicos y biológicos a lo largo de los diferentes estudios, son elementos imprescindibles para alcanzar óptimos resultados. En este trabajo se seleccionó una metodología para la validación del método analítico empleado en la determinación de ribosa por el método del orcinol y se utilizó una solución estándar de ribosa (0,025 mg/mL). Se realizó un análisis de los criterios fundamentales de validación: linealidad, precisión, exactitud, sensibilidad, especificidad, límites de detección y robustez. Se comprobó la utilidad de dicho procedimiento y se demostró mediante el diseño experimental y los procedimientos estadísticos empleados que dicho método es lineal (r2>0,98), exacto (Fexp.< Ftab. y texp. < ttab.), preciso (CV&lt;3 %), sensible (LD = 1 ug/mL y LC = 3.3 ug/mL) y específico (respuesta no significativa), por lo cual es confiable. La determinación de ribosa es una técnica colorimétrica que cuantifica pentosas y se emplea con el objetivo de conocer el contenido exacto de la misma en una muestra de producto purificado. Además es empleada como control final según la OMS en las vacunas conjugadas de Haemophilus influenzae.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[The appropriate standardization of an analytical assay, followed by the validation of the method and the homogeneity of the chemical and biological reagents used during the different studies are indispensable elements for obtaining optimal results. In this work a methodology was selected for the validation of the analytical method used to determine ribose by the orcinol method using a standard ribose solution (0,025 mg/mL). An analysis of the main validation criteria: linearity, precision, accuracy, sensitivity, specificity, detection limits and robustness were carried out. The usefulness of this procedure was demonstrated and by means of the experimental design and the statistical procedures used, the linearity (r2>0,98), exactness (Fexp. <Ftab. and texp. <ttab.), preciseness (CV<3%), sensitivity (LD = 1 ug/mL and LC = 3.3 ug/mL) and specificity (non significant answer) of the method were verified, for which reasons it is considered reliable. The determination of ribose is a colorimetric assay that quantifies pentoses and is used with the objective of knowing the exact pentose contents in a sample of purified product. It is also used as a final control for Haemophilus influenzae conjugated vaccines according to WHO.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Orcinol]]></kwd>
<kwd lng="es"><![CDATA[ribosa]]></kwd>
<kwd lng="es"><![CDATA[validación]]></kwd>
<kwd lng="es"><![CDATA[Haemophilus influenzae]]></kwd>
<kwd lng="en"><![CDATA[Orcinol]]></kwd>
<kwd lng="en"><![CDATA[ribose]]></kwd>
<kwd lng="en"><![CDATA[validation]]></kwd>
<kwd lng="en"><![CDATA[Haemophilus influenzae]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>ARTICULOS ORIGINALES</strong></font></p>     <p align="right">&nbsp;</p>     <p align="right"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong><font size="4">Validaci&oacute;n de una t&eacute;cnica colorim&eacute;trica para la  determinaci&oacute;n de carbohidratos. </font></strong></font></p>     <p align="right">&nbsp;</p>     <p align="right"><strong><font size="3" face="Verdana, Arial, Helvetica, sans-serif">Validation of a colorimetric technique for carbohydrate determination.</font></strong></p>     <p align="left"><strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">    <br> </font></strong></p>     <p align="left"><strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Carmen Soto, Maribel Cuello, Yusim&iacute; Alfonso, Osmir Cabrera y Gustavo Sierra.    <br> </font></strong></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Instituto Finlay. Centro de Investigaci&oacute;n-Producci&oacute;n de Vacunas y Sueros. Ciudad de La Habana, Cuba.    ]]></body>
<body><![CDATA[<br>   E-mail: <a href="mailto:csoto@finlay.edu.cu">csoto@finlay.edu.cu</a></font></p> <hr>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>RESUMEN</strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> La adecuada estandarizaci&oacute;n de un ensayo anal&iacute;tico, seguido de la validaci&oacute;n del m&eacute;todo y la homogeneidad    de los reactivos qu&iacute;micos y biol&oacute;gicos a lo largo de los diferentes estudios, son elementos imprescindibles    para alcanzar &oacute;ptimos resultados. En este trabajo se seleccion&oacute; una metodolog&iacute;a para la validaci&oacute;n del    m&eacute;todo anal&iacute;tico empleado en la determinaci&oacute;n de ribosa por el m&eacute;todo del orcinol y se utiliz&oacute; una soluci&oacute;n    est&aacute;ndar de ribosa (0,025 mg/mL). Se realiz&oacute; un an&aacute;lisis de los criterios fundamentales de validaci&oacute;n:   linealidad, precisi&oacute;n, exactitud, sensibilidad, especificidad, l&iacute;mites de detecci&oacute;n y robustez. Se comprob&oacute; la    utilidad de dicho procedimiento y se demostr&oacute; mediante el dise&ntilde;o experimental y los procedimientos    estad&iacute;sticos empleados que dicho m&eacute;todo es lineal (r2&gt;0,98), exacto (Fexp.&lt; Ftab. y texp. &lt; ttab.), preciso    (CV&lt;3 %), sensible (LD = 1 ug/mL y LC = 3.3 ug/mL) y espec&iacute;fico (respuesta no significativa), por lo cual    es confiable. La determinaci&oacute;n de ribosa es una t&eacute;cnica colorim&eacute;trica que cuantifica pentosas y se emplea    con el objetivo de conocer el contenido exacto de la misma en una muestra de producto purificado. Adem&aacute;s    es empleada como control final seg&uacute;n la OMS en las vacunas conjugadas de Haemophilus influenzae.    <br>   </font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Palabras claves:</strong> Orcinol, ribosa, validaci&oacute;n, Haemophilus influenzae.</font></p> <hr>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">  <strong>Abstract</strong></font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">    <br>   The appropriate standardization of an analytical assay, followed by the validation of the method and the    <br>   homogeneity of the chemical and biological reagents used during the different studies are indispensable elements for    obtaining optimal results. In this work a methodology was selected for the validation of the analytical method used    to determine ribose by the orcinol method using a standard ribose solution (0,025 mg/mL). An analysis of the main    validation criteria: linearity, precision, accuracy, sensitivity, specificity, detection limits and robustness were carried    out. The usefulness of this procedure was demonstrated and by means of the experimental design and the    statistical procedures used, the linearity (r2&gt;0,98), exactness (Fexp. &lt;Ftab. and texp. &lt;ttab.), preciseness    (CV&lt;3%), sensitivity (LD = 1 ug/mL and LC = 3.3 ug/mL) and specificity (non significant answer) of the method    were verified, for which reasons it is considered reliable. The determination of ribose is a colorimetric assay that    quantifies pentoses and is used with the objective of knowing the exact pentose contents in a sample of purified    product. It is also used as a final control for Haemophilus influenzae conjugated vaccines according to WHO.    <br> </font></p>     ]]></body>
<body><![CDATA[<p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Keywords:</strong> Orcinol, ribose, validation, Haemophilus influenzae</font></p> <hr>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">texto completo en pdf</font></p>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>BIBLIOGRAFIA</strong></font></p>     <!-- ref --><p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Levine OS, Granoff D, Lagos R, Fritzell B, Levine MM. Factors associated with a superior antibody response to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age Vaccine 1997;15:325-328. </font><!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Anderson EC, Begg SC, Crawshaw SC, Hargreaves RM, Howard RM, Slack MPE. Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the prevacination (1992-1994). Epidemiol Infect 1995;115:89-100. </font>    <P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Phillip P, Ronald WE. Biological Activity of Conjugate. Suplement 9;1991. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Slack MPE. Invasive Haemophilus influenzae disease: the impact of Hib immunisation. J med. Microbilo 1995;42:75-77. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Fern&aacute;ndez, A. Rosales, I. Validaci&oacute;n de M&eacute;todos Anal&iacute;ticos. Segundo taller Nacional de Validaci&oacute;n (Notas del curso). 1999. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. WHO. Proposed Draft Requirements for Haemophilus influenzae type b.1990;46:9-15. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Chaloner-Larsson G, Anderson R, Egan A. A WHO guide to good manufacturing practice (GMP) requirements. Part 2: Validation. Validation of analytical assays. WHO Geneva 1997:65-95. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Gordon LK, inventors. Polysaccharide exotoxoid conjugate vaccine.     US Patent. 4,619,828. 1986. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Rampazoo P. Standarisation and Validation of Analytical Methods in the Pharmaceutical Industry. II F&aacute;rmaco 1990;45:807-15. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Kriskern PJ, Hagopian JA, and Carlos DJ, inventors. Meningitis vaccine.     US Patent. 430,708. 1980. </font>     <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Calpena AC, Escribano E, Fern&aacute;ndez C. Validaci&oacute;n de los m&eacute;todos anal&iacute;ticos. Farm Clin 1991;7(9):749-58. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Thielmann K. Principios de metodolog&iacute;a en bioqu&iacute;mica cl&iacute;nica. ed. Organismos: Instituto Cubano del Libro, 1973 </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ochoa RA, Mart&iacute;nez, J.C; Estrada, E et al. Principios y procedimientos para la validaci&oacute;n de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad  de vacunas. VacciMonitor 1999;8(10):9-13. </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Green, M. A practical guide to analytical method validation. Analytical Chemestry 1996; 68: 305A-309A </font>    <!-- ref --><P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Aguilar G, Alc&aacute;ntara A, Ch&aacute;rvel A, Garc&iacute;a JL, Garz&oacute;n A, Guerrero ME, et al. Validaci&oacute;n de m&eacute;todos anal&iacute;ticos. Comit&eacute; de Elaboraci&oacute;n de Gu&iacute;as Oficiales de Validaci&oacute;n de la Direcci&oacute;n General de Control de Insumos para la Salud, SSA. Colegio Nacional de Qu&iacute;micos Farmac&eacute;uticos Biol&oacute;gicos. M&eacute;xico AC, 1992. </font>    <P ALIGN="JUSTIFY"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Castro M, Gasc&oacute;n S, Pujol M, Sans JM, Vicente L. Validaci&oacute;n de m&eacute;todos anal&iacute;ticos. Asociaci&oacute;n Espa&ntilde;ola de Farmac&eacute;uticos de la Industria. Monograf&iacute;a AEFI. Secci&oacute;n Catalana. Comisi&oacute;n de Normas de Buena Fabricaci&oacute;n y Control de la Calidad. Edici&oacute;n Hewlett Packard, 1989.</font>     <p align="left">&nbsp; </p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
<name>
<surname><![CDATA[Granoff]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lagos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fritzell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Factors associated with a superior antibody response to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>1997</year>
<volume>15</volume>
<page-range>325-328</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Begg]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Crawshaw]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Hargreaves]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Slack]]></surname>
<given-names><![CDATA[MPE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the prevacination (1992-1994)]]></article-title>
<source><![CDATA[Epidemiol Infect]]></source>
<year>1995</year>
<volume>115</volume>
<page-range>89-100</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slack]]></surname>
<given-names><![CDATA[MPE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Invasive Haemophilus influenzae disease: the impact of Hib immunisation]]></article-title>
<source><![CDATA[J med Microbilo]]></source>
<year>1995</year>
<volume>42</volume>
<page-range>75-77</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>5</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Validación de Métodos Analíticos]]></source>
<year>1999</year>
<conf-name><![CDATA[Segundo taller Nacional de Validación]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>6</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Proposed Draft Requirements for Haemophilus influenzae type b]]></source>
<year>1990</year>
<page-range>9-15</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaloner-Larsson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Egan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A WHO guide to good manufacturing practice (GMP) requirements: Part 2: Validation]]></article-title>
<source><![CDATA[Validation of analytical assays]]></source>
<year>1997</year>
<page-range>65-95</page-range><publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
</person-group>
<source><![CDATA[Polysaccharide exotoxoid conjugate vaccine]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rampazoo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[II. FármacoStandarisation and Validation of Analytical Methods in the Pharmaceutical Industry]]></source>
<year>1990</year>
<volume>45</volume>
<page-range>807-15</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>10</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kriskern]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hagopian]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[DJ]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
</person-group>
<source><![CDATA[Meningitis vaccine]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calpena]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Escribano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Validación de los métodos analíticos]]></article-title>
<source><![CDATA[Farm Clin]]></source>
<year>1991</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>749-58</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thielmann]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Principios de metodología en bioquímica clínica]]></source>
<year>1973</year>
<publisher-name><![CDATA[Instituto Cubano del Libro]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Principios y procedimientos para la validación de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad de vacunas]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>1999</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>14</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[M A]]></given-names>
</name>
</person-group>
<source><![CDATA[Practical guide to analytical method validation: Analytical Chemestry]]></source>
<year>1996</year>
<page-range>305A-309A</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Alcántara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chárvel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Garzón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Validación de métodos analíticos: Comité de Elaboración de Guías Oficiales de Validación de la Dirección General de Control de Insumos para la Salud, SSA]]></article-title>
<collab>Colegio Nacional de Químicos Farmacéuticos Biológicos</collab>
<source><![CDATA[]]></source>
<year>1992</year>
<publisher-loc><![CDATA[México^eAC AC]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B15">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gascón]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pujol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sans]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Validación de métodos analíticos]]></article-title>
<collab>Asociación Española de Farmacéuticos de la Industria</collab>
<source><![CDATA[Comisión de Normas de Buena Fabricación y Control de la Calidad]]></source>
<year>1989</year>
<publisher-name><![CDATA[Edición Hewlett Packard]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
